Latest RedHill Biopharma News & Updates

See the latest news and media coverage for RedHill. We track all announcements, press releases, and industry mentions in real time, all in one place.

RedHill Biopharma (RedHill)

Specialty pharmaceutical company

redhillbio.com

Headquarters: Raleigh, United States
Founded year: 2009
Company type: Public company
Number of employees: 50–200
Industry: Pharmaceuticals

Last updated Today

Latest news about RedHill Biopharma (RedHill)

In short: RedHill raised $19.4 million, regained Nasdaq compliance, and secured $10.9 million in legal judgments while advancing its drug pipeline.

Company announcements

June 18 RedHill

RedHill announces up to $19.4 million private placement

$6 million upfront with potential $13.4 million from warrants for product acquisition and working capital.

June 9 RedHill

RedHill's opaganib gets FDA rare pediatric disease designation

The designation adds to existing orphan drug status for neuroblastoma and offers development incentives including a Priority Review Voucher.

June 8 RedHill

RedHill commences enforcement of $10.9M judgment against Kukbo

The New York Supreme Court final judgment includes principal and legal fees, with proceedings ongoing in Korea.

June 2 RedHill

RedHill advancing opaganib for Ebola outbreak biodefense

Opaganib shows potential dual mechanism and mortality reduction in severe COVID-19, with preclinical Ebola activity.

Media coverage

June 18 Yahoo Finance

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced private placement for the...

June 13 The Globe and Mail

RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak

Detailed price information for Redhill Biophrma ADR (RDHL-Q) from The Globe and Mail including charting and trades.

June 9 Yahoo Finance

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

April 30 Morningstar

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease | Morningstar

RHB-204 is patent protected through ... and EU Orphan Designation (eligibility for 10 years EU market exclusivity) for NTM disease caused by MAC5 · The...

Never miss news about RedHill

Track RedHill and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

RedHill competitors & trending companies

Browse news for competitors to RedHill and other trending companies.